Ask AI
Barriers to CAR T Cell Therapy

CE / CME

From Evidence to Practice—Barriers to Access and Manufacturing Delays in CAR T-Cell Therapy

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: December 09, 2025

Expiration: June 08, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Hwa YL, Doss D, Mangan PA, et al. Understanding the role and clinical management of bridging therapy during CAR T-cell therapy for relapsed or refractory multiple myeloma. J Adv Pract Oncol. 2025;[Epub ahead of print].
  2. Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388:1002-1014.
  3. San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389:335-347.
  4. Idecabtagene vicleucel [prescribing Information]. Summit, NJ: Celgene Corporation, a Bristol-Myers Squibb Company; 2025.
  5. Ciltacabtagene autoleucel [prescribing Information]. Horsham, PA: Janssen Biotech, Inc; 2025.
  6. Mikhael J, Fowler J, Shah N. Chimeric antigen receptor T-cell therapies: barriers and solutions to access. JCO Oncol Pract. 2022;18:800-807.
  7. Baker D, Bimali M, Carrillo L, et al. Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica. 2021;106:3215-3218.
  8. Atodaria K, Sripathi K, Varma S, et al. Survival following quadruplet and triple therapy in transplant in-eligible multiple myeloma - a meta-analysis of recent clinical trials. Blood. 2024;144(suppl 1):3351.
  9. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: multiple myeloma. v.2.2026. nccn.org. Accessed December 3, 2025. 
  10. Borrello I. Can we change the disease biology of multiple myeloma? Leuk Res. 2012;36 Suppl 1(0 1):S3-S12.
  11. Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10:94.
  12. Richardson PG, San Miguel JF, Moreau P, et al. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018;8:109.
  13. Delea T, Moynahan A, Ge W, et al. Real-world study of patients with triple-class exposed relapsed/refractory multiple myeloma: analysis across a spectrum of advanced disease stage Medicare patients in the United States. Blood. 2023;142(suppl 1):3773.
  14. Perrot A, Hulin C, Macro M, et al. Real-life survival data after triple-exposure to proteasome inhibitors (PI), immunomodulators (IMID) and anti-CD38 in multiple myeloma patients in the Emmy cohort. Blood. 2021;138(suppl 1):3764.
  15. Mohan M, Van Oekelen O, Akhtar OS, et al. Charting the course: sequencing immunotherapy for multiple myeloma. Am Soc Clin Oncol Educ Book. 2024;44:e432204.
  16. Dhakal B, Einsele H, Schecter JM, et al. Real-world treatment patterns and outcomes in relapsed/refractory multiple myeloma (1-3 prior lines): Flatiron database. Blood Adv. 2024;8:5062-5071.
  17. Bal S, Costa LJ. Bridging treatment prior to chimeric antigen receptor T-cell therapy in multiple myeloma. Br J Haematol. 2024;204:449-454.
  18. Mateos MV, San-Miguel J, Dhakal B, et al. Overall survival (OS) with ciltacabtagene autoleucel (cilta-cel) versus standard of care (SOC) in lenalidomide (Len)-refractory multiple myeloma (MM): phase 3 CARTITUDE-4 study update. Presented at: 2025 European Society for Blood and Marrow Transplantation Annual Meeting; March 30 - April 2, 2025. Abstract OS14-02.
  19. Voorhees PM, Martin TG, Lin Y, et al. Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM). Presented at: 2025 American Society of Clinical Oncology Annual Meeting; May 30 - June 3, 2025. Abstract 7507.
  20. Sidana S, Patel KK, Peres LC, et al. Safety and efficacy of standard of care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma. Blood. 2025;145:85-97.
  21. Wesson W, Dima D, Suleman N, et al. Timing of toxicities and non-relapse mortality following CAR T therapy in myeloma. Transplant Cell Ther. 2024;30:876-884.
  22. ‌Hansen DK, Sidana S, Peres LC, et al. Idecabtagene vicleucel for relapsed/refractory multiple myeloma: real-world experience from the Myeloma CAR T Consortium. J Clin Oncol. 2023;41:2087-2097.
  23. ‌Fonseca R, Tran D, Laidlaw A, et al. Impact of disease progression, line of therapy, and response on health-related quality of life in multiple myeloma: a systematic literature review. Clin Lymphoma Myeloma Leuk. 2023;23:426-437.e11.
  24. Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705-716.
  25. Lin Y, Martin TG, Usmani SZ, et al. CARTITUDE-1 final results: phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma. J Clin Oncol. 2023;41:8009.
  26. ‌Dave H, Jerkins L, Hanley PJ, et al. Driving the CAR to the bone marrow transplant program. Curr Hematol Malig Rep. 2019;14:561-569.
  27. ‌‌Ailawadhi S, Arnulf B, Patel K, et al. Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. Blood. 2024;144:2389-2401.